Pharma: Page 2

  • Image attribution tooltip
    National Cancer Institute, NIH

    Amgen data supports KRAS cancer drug, but survival benefit remains in question

    Results from the company’s Phase 3 study show Lumakras outperformed chemotherapy. But that effect didn’t translate into patients living longer.

    By Sept. 12, 2022
  • Man looking at paperwork with graphs at desk
    Image attribution tooltip
    Permission granted by TrialCard
    Sponsored by Policy Reporter

    Keeping track of changing payer formulary positioning and coverage

    You need current, reliable data, but other factors are critical in assessing this information.

    Sept. 12, 2022
  • Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers gets FDA approval for new type of psoriasis drug

    Sotyktu has been on the pharma’s top pipeline candidates and its clearance continues a string of positive regulatory news for the company.

    By Updated Sept. 12, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images

    Moderna says US COVID-19 vaccine market could be worth $13B a year

    The high end of the company’s estimates assumes a $100 price per dose and that half of all U.S. adults will receive a yearly booster.

    By Sept. 9, 2022
  • Image attribution tooltip
    Jeff J Mitchell via Getty Images
    Deep Dive

    Can biosimilars, after years of limited impact, finally make a mark in the US?

    Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.

    By Sept. 7, 2022
  • Image attribution tooltip
    Kevin C. Cox via Getty Images

    CDC backs updated COVID shots from Pfizer, Moderna

    One day after the FDA’s authorization, the CDC recommended the companies’ omicron-targeted vaccines for most adults and children over 12 years old.

    By Sept. 2, 2022
  • A photo of Jay Bradner, former head of the Novartis Institutes for BioMedical Research
    Image attribution tooltip
    Courtesy of Novartis

    Novartis’ Bradner steps down as research head amid company shake-up

    Jay Bradner, a well-known physician scientist who pushed to make Novartis more accessible to biotech startups, will be replaced by Merck executive Fiona Marshall in November.

    By Sept. 1, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA clears updated COVID-19 boosters from Pfizer, Moderna

    The new shots, which are designed to better target circulating strains of omicron, could be available within days.

    By Aug. 31, 2022
  • Portrait of a brown-haired man in white dress shirt smiling at the camera.
    Image attribution tooltip
    Permission granted by Pfizer

    Pfizer lures first chief marketing officer from Verily

    Drew Panayiotou led marketing efforts at Alphabet’s life sciences arm Verily, and his appointment is Pfizer’s third senior-level hire this year.

    By Aug. 31, 2022
  • AstraZeneca, matching Lilly, reports positive heart failure data for diabetes pill

    The new data position AstraZeneca to significantly expand use of Farxiga in heart failure and compete with Lilly and Boehringer Ingelheim’s rival drug Jardiance. 

    By Aug. 29, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images

    Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology

    The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.

    By Aug. 26, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    Pfizer follows GSK with positive Phase 3 results for RSV vaccine

    In a pre-planned interim data analysis, Pfizer said its shot was strongly protective against severe disease and plans to submit the results to regulators this fall.

    By Aug. 25, 2022
  • Image attribution tooltip
    Jacob Bell

    Novartis begins plans to spin off generic drug business

    After reviewing multiple options including a possible sale, the Swiss drugmaker said spinning off Sandoz would give the division “greater freedom to operate” and capitalize on newly growing sales.

    By Aug. 25, 2022
  • A 3D illustration of an intranuclear neuronal inclusion
    Image attribution tooltip
    Dr_Microbe via Getty Images

    Safety worries spur Novartis to suspend drug dosing in Huntington’s trial

    Researchers reported signs of nerve damage in patients treated with the drug branaplam, which is among the most advanced candidates now in testing.

    By Aug. 24, 2022
  • A sign at Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences

    Gilead breaks through with first approval for new HIV drug

    European authorities cleared Gilead’s long-acting shot for patients whose HIV infection is resistant to other drugs. An FDA decision is expected by December.

    By Aug. 22, 2022
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi

    Sanofi ends development of breast cancer drug in another blow to pipeline

    The French drugmaker’s shares fell by more than 6% after the once promising treatment, called amcenestrant, failed its second major trial this year.

    By Kristin Jensen • Aug. 17, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images

    UK approves Moderna’s two-pronged COVID-19 booster

    Britain’s drug regulator is the first public health authority to clear a vaccine designed to fight omicron as well as the original strain of the virus. 

    By Aug. 15, 2022
  • Image attribution tooltip

    Novartis bid to repurpose rare disease drug for cancer falls short in third trial

    A study testing Novartis’ canakinumab as an adjuvant lung cancer treatment missed its main goal, closing off an opportunity for an expanded approval.

    By Aug. 15, 2022
  • A doctor with a white lab coat looking at a computer on a table full of papers
    Image attribution tooltip
    Retrieved from Shutterstock.
    Sponsored by Veradigm

    Messaging the right HCP at the right time via their electronic health record (EHR)

    HCPs spend 3x the time in their EHR each day as they do online. How should that affect your approach to reaching HCPs?

    Aug. 15, 2022
  • Image attribution tooltip
    Jeenah Moon via Getty Images

    Pfizer’s new pneumococcal vaccine meets study goal in children

    Pfizer, which competes with Merck in this market, plans to ask the FDA for an expanded approval of its 20-valent shot later this year.

    By Aug. 12, 2022
  • Sen Ron Wyden sits behind a wooden podium with a microphone.
    Image attribution tooltip
    Sarah Silbiger / Stringer via Getty Images

    Amgen’s low tax rates draw attention of top Democratic senator

    Ron Wyden, D-Ore., is probing how Amgen paid an average effective tax rate of 12% over the past four years, well below the U.S. statutory rate of 21%.

    By Aug. 12, 2022
  • In this photo illustration, packages and pills of Zantac sit on a table on September 19, 2019 in New York City.
    Image attribution tooltip
    Drew Angerer via Getty Images

    GSK, Pfizer, Sanofi shares drop amid Zantac litigation concerns

    The companies could face liability related to their sales of the heartburn drug, which was withdrawn from the market in the U.S. and other countries after impurities related to a likely carcinogen were detected.

    By Updated Aug. 11, 2022
  • Alexis Borisy and Melanie Nallicheri of EQRx, at launch
    Image attribution tooltip
    Courtesy of EQRx

    EQRx, in bid to compete, takes on AstraZeneca’s top seller in head-to-head trial

    The study could be critical for a medicine EQRx plans to position as a competitor to Tagrisso. The drug is under review in the U.K., a first for EQRx.

    By Kristin Jensen • Aug. 11, 2022
  • A worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax in Berlin, Germany in February 2022.
    Image attribution tooltip
    Carsten Koall via Getty Images

    Novavax slashes revenue forecasts amid slow demand for COVID-19 vaccine

    The biotech now expects about $2 billion in revenue in 2022, less than half its previous estimates, after sales fell sharply in the second quarter.

    By Aug. 9, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J’s head of R&D departs as pharma’s leadership turns over

    Mathai Mammen is leaving to “pursue other opportunities,” J&J said in an abrupt announcement. William Hait, currently head of external innovation, will take Mammen’s place in the interim.

    By Aug. 9, 2022